I'm not referring to INSM. It would be wrong to call that particular descent slow.... I'm actually referring to the results this board has collectively achieved by completely ignoring the boards false idol. I believe that Insmed will be moving back up quite quickly, and pretty soon. Any form of sanity will never return to the vainglorious one!
Jad, he just is not worth responding to or even clicking on the thumbs down logo. If you look back at all of the last 50 posts on this board you will see that he actually spent hours logging in and out just to thumbs down our posts and thumbs up his. That's called obsession, and is probably best dealt with by totally and completely ignoring anything he ever has to say. I know it's hard, but he just isn't worth the time to punch a key..... BTW, I found it really interesting when bwd posted that Eleison is making progress with pediatric osteosarcoma and also really interesting when checks pointed out that they are moving forward with a large trial focused on non small cell lung cancer. Somewhere in the area of 90% of lung cancers are the non small cell type....
It is currently up over 5% and none of the top ten IBB components are up more than 4%. The Leerink sit down was likely a positive, but there are some other very near term potential catalysts.
The company should be filing it's IND for the phase I PAH trial.
The company may be announcing that the phase III CONVERT study is fully enrolled
The company may be announcing the acquisition of an additional asset, likely on the cheap after the past few weeks.
The FDA PDUFA5 for NTM is scheduled for the 15th of October.
Potential for yet another indication using the company platform.
I always like to look at leading gainers in biotech, and a few days ago ZSPH led the pack. The company had cancelled out of a conference starting buyout rumors, later confirmed. 15 billion Swedish drug giant Actelion has been in talks to purchase the company. I checked out Actelion and was really surprised to find out that there leading drug by far is Tracleer, for the treatment of Pulmonary Arterial Hypertension - PAH. Sales for Tracleer, now off patent, border on 2 billion! Insmed expects to start a clinical trial for INS1009 in Q4 for the treatment of PAH and believe they may qualify for a 505(b)(2) path to approval. I wasn't aware of the sales potential for this drug using the Insmed platform that is hardly discussed here.
The company doesn't list any revenue projections so whoever is saying over and over that the company dropped revenue projections for CF is......right.....I guess.
The European app is for NTM and CF, so with approval the company can market LAI for just NTM or both, it will be entirely up to Insmed management.
The most important info provided is the one year post 112 study data. Of the total 23 patients given both LAI and placebo that converted, just one died. Of the 66 that did not convert 9 have already died. That type of info makes it pretty clear that culture conversion should have been the focus from the beginning.....
Well, when I spent over 30 minutes yesterday listening to the May Dr. Olivier presentation, he seemed to agree with the statements you just made. After discussing LAI he touched on other potential drugs that are currently used to fight TB, but they all had toxic side effects.
Since the presentation was all about NTM, he didn't say that LAI could potentially treat TB, but applying any type of deductive logic one may arrive at that premise.
"remember that only small people need to make themselves look big" which is milder and more gentle than "There is only one certain cure for an egotistic boaster, surgery, amputation at the neck" Which obviously means that other boards also have there clowns..... For those that keep track, INSM is currently 16% off its annual high, the IBB ETF is 16% off its annual high, and the NBI is 16% off its annual high. That has me reaching the conclusion that biotech stocks are down about 16% from their highs.
Part of me says that just to tick off brainboy, but seriously, this current trial is open label - if cultures are negative the patients and the docs know if LAI was involved.... Since the study is confirmatory and if the conversions in the LAI arm are 3 or 4 to 1, then WHY NOT just stop the trial.... That is a question NTM patients are likely to ask at the October meeting
As the madness continues on this board, I noticed today that the presentations from the May 15th NTM patient and physician meeting are now available in video format online. I listened to 30 some minutes of Dr. Oliviers speech titled NTM Whats New. He talks about LAI from the 17 or 18 minute mark, until about the 23 or 24 minute mark if anyone feels like listening. NTM Info and Research has links to all the videos from that session. Dr. Olivier is also speaking today at 1:00 Eastern time at the FDA sponsored meeting. In the video from May he basically says that culture conversion was not expected, and that more recent data seems to strengthen the data of those that were given LAI. Of course, it's five months later and even more data is now available....
Go away clone, although it is somewhat old news IMO, at the end of May poster 612 appeared on the Insmed website and remains on the site under presentations. The number of patients that have had culture conversions is up significantly from the original report and there was a significantly positive difference in the walk test for those that had culture conversion over those that did not. The number of conversions for those taking the standard meds but placebo rather than Arikayce remained at just 4.
That's how long it took her to develop a plan to rein in the cost of prescription drugs. One day. Hedge funds and money managers spend thousands of hours putting together portfolios, but she has a complete and total plan to change the cost structure of prescription drugs..... in one day! Politics or Brilliance?
is 100% spot on, and I'm just as guilty. I will never again respond to our king of clowns....although I may mention things like billions, iPLEX, and the uptick rule.... just to make sure he doesn't forget to take his blood pressure meds
Several years ago when Insmed bought Transcript nobody had really ever heard of NTM. It's awful. I can't believe that some NTM patients that have been swallowing a cache of pills everyday to no avail,, and have read about the culture conversions on the NTM Info and News website , won't either attend or log in to the meeting and beg for compassionate use of LAI. I mean, that is exactly what I would do if myself or one of my loved ones had this horrible affliction. Unlike iPLEX when ALS victims fought for and was granted compassionate use. there is plenty of LAI to go around. If nothing else it will be interesting to read about the meeting, the comments, and the suggestions - especially since the organizers are the same that would ultimately approve or turn down LAI.
We have been told over and over and over that ROP is the only medical condition that has any use for Insmeds old shelved protein complex....are you saying that claim isn't true?
"to finally show the board" lol You are nearly always good for a laugh, but that takes first prize!! Come 'on king trader, whats your pick for tomorrow? I know, I know, you will tell us after the fact tomorrow.......go study that uptick rule that was abolished over 8 years ago, talk about foot in mouth!!
I think it's great that you spoke with your formulary, good for you, although I know you could not name said formulary because you actually spoke with no one.
The World Health Organization classifies pulmonary hypertension into five groups, with the first being Pulmonary Arterial Hypertension - PAH. Tracleer is for this WHO class 1 group and pricing is listed at around 8500.00 per month regardless of what your formulary says. INS1009 is designed as a WHO class 1 drug also. Your point is wrong.
INS1009 has not even started a phase I trial yet, but has already spoken with the FDA regarding a 505(b)(2) filing if they get to that point. Tracleer has some pretty rough side effects. The smaller 7 billion dollar market cap UTHR got tyvaso to market in 2010. Tyvaso is inhaled 4 times daily and is intended to have fewer potential side effects than Tracleer, but causes an awful cough..... four times a day. Still, it's sales top 400 million. INS1009 is intended to be used just once daily and in animal studies has caused virtually no coughing. Insmed has a long way to go, but this is an enormous market in terms of dollars.
I skipped talking to my formulary and just did some homework.
That's funny bwd, Martin Shkreli from Touring has been labeled "the most hated person" by biotech investors, but hate is such a strong word..... Unfortunately the one that you refer to could not be caught in the same boat because his trades are only imaginary, and apparently Mr. Campbell really was short.
Jad, I'm sidelined for a few days and don't have much to do but watch tv, read, or rip Terry..... While his true motives are not known, any logical person knows this:
He doesn't really surf, at least not on water. All the innovations in technology don't yet include a device that can be used to post on a surf board, and he is always, always here.
He doesn't know how to actually short a stock. His post a few years ago about the abolished uptick rule made that absolutely, abundantly clear.
He is totally obsessed with Kevin. (I find that somewhat scary)
A single word,,, iPLEX, drives him into a complete frenzy. I don't know, maybe he is like five foot one and couldn't wait until he could use the drug which was then pulled?
He isn't very creative, as is obvious by his reposting his own messages over and over.
He has multiple ID's, your last post receiving multiple thumbs down within minutes make that obvious.
We could all put him on ignore, but in a weird way I get some comedy relief nearly every time he puts up a post.
He has no friends. How could someone that spends the middle of the night until the following evening have time for friendships?
He remains the only person in my years of reading message boards that carries on conversations with..... himself.
I doubt if this even touches the surface of bizarro boys true nature.....
Well, I can't stand politics, but it would seem to me like she just made a multi billion dollar enemy. The U.S. is by far the leader in drug development, and I suppose she figures why should the U.S. lead the world in anything anymore.....